People
Seres Therapeutics Names von Moltke as Chief Medical Officer
7 April 2020 - - US-based microbiome therapeutics platform company Seres Therapeutics, Inc., (NASDAQ: MCRB) has appointed Lisa von Moltke, M.D., FCP, as executive vice president and chief medical officer, the company said.

Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology.

Dr. von Moltke most recently served as senior vice president and Head of Clinical Development at Alkermes.

Prior to that, she held positions as vice president of Clinical and Exploratory Pharmacology at Sanofi Genzyme and Senior director of Translational Medicine at Millennium Pharmaceuticals/Takeda Oncology.

She has served as president of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned her B.A. degree at Wellesley College and her M.D. from Michigan State University College of Human Medicine.

She trained in internal medicine at New England Medical Center Hospital and started her career as a clinical pharmacology fellow at Tufts University School of Medicine and New England Medical Center Hospital.

Seres Therapeutics, Inc., (NASDAQ: MCRB) is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.

Seres' SER-287 programme has obtained Fast Track and Orphan Drug designation from the US Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis.

Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection.

Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma and SER-301 for ulcerative colitis.
Login
Username:

Password: